Item 16. Form 10-K Summary
4K characters. Original on sec.gov ·
Item 16. Form 10-K Summary
Not applicable.
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Eli Lilly and Company
| By | /s/ David Ricks | |||||||
| David Ricks | ||||||||
| Chair, President, and Chief Executive Officer |
February 22, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 22, 2023 by the following persons on behalf of the Registrant and in the capacities indicated.
| Signature | Title | |||||||
| /s/ David Ricks | Chair, President, and Chief Executive Officer (principal executive officer) | |||||||
| DAVID RICKS | ||||||||
| /s/ Anat Ashkenazi | Executive Vice President and Chief Financial Officer (principal financial officer) | |||||||
| ANAT ASHKENAZI | ||||||||
| /s/ Donald Zakrowski | Senior Vice President, Finance, and Chief Accounting Officer (principal accounting officer) | |||||||
| DONALD ZAKROWSKI | ||||||||
| /s/ Ralph Alvarez | Director | |||||||
| RALPH ALVAREZ | ||||||||
| /s/ Katherine Baicker, Ph.D. | Director | |||||||
| KATHERINE BAICKER, Ph.D. | ||||||||
| /s/ Erik Fyrwald | Director | |||||||
| ERIK FYRWALD | ||||||||
| /s/ Mary Lynne Hedley, Ph.D. | Director | |||||||
| MARY LYNNE HEDLEY, Ph. D. | ||||||||
| /s/ Jamere Jackson | Director | |||||||
| JAMERE JACKSON | ||||||||
| /s/ Kimberly Johnson | Director | |||||||
| KIMBERLY JOHNSON | ||||||||
| /s/ William Kaelin, Jr., M.D. | Director | |||||||
| WILLIAM KAELIN, JR., M.D. | ||||||||
| /s/ Juan Luciano | Director | |||||||
| JUAN LUCIANO | ||||||||
| /s/ Marschall Runge, M.D., Ph.D. | Director | |||||||
| MARSCHALL RUNGE, M.D., Ph.D. | ||||||||
| /s/ Gabrielle Sulzberger | Director | |||||||
| GABRIELLE SULZBERGER | ||||||||
| /s/ Jackson Tai | Director | |||||||
| JACKSON TAI | ||||||||
| /s/ Karen Walker | Director | |||||||
| KAREN WALKER |
Trademarks Used In This Report
Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol ® or ™, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.
Byetta® is a trademark of Amylin Pharmaceuticals, Inc.
Glyxambi®, Jardiance®, Jentadueto®, Synjardy®, Trajenta®, and Trijardy® are trademarks of Boehringer Ingelheim International GmbH.
Tyvyt® is a trademark of Innovent Biologics (Suzhou) Co., Ltd.
Previous: Item 15. Exhibits and Financial Statement Schedules